SCHEMBL17895256

SCHEMBL17895256

CC(=O)N[C@@H](C=O)[C@@H](O)[C@@](N)(O)[C@@H](C)O

nearest known ligand 0.44

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PAX8 Q06710 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4957751 0.73 ALDH1A1 (0.34) PAX8
SCHEMBL28159972 0.71
SCHEMBL1764290 0.71
SCHEMBL5464777 0.71 ALDH1A1 (0.35)
SCHEMBL1657294 0.71 ALDH1A1 (0.35)
SCHEMBL9484445 0.71 ALDH1A1 (0.35)
SCHEMBL5841143 0.70 TP53 (0.30)
SCHEMBL524648 0.68 PAX8 (0.32) PAX8
SCHEMBL6384699 0.68 PAX8 (0.32) PAX8
SCHEMBL702670 0.68 PAX8 (0.32) PAX8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559731-B2 Mutated PglB oligosaccharyl transferase enzymes GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2026-02-24 US disclosed
US-20250270520-A1 MUTATED PGLB OLIGOSACCHARYLTRANSFERASE ENZYMES GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2025-08-28 US disclosed
EP-4389908-A2 MUTATED PGLB OLIGOSACCHARYLTRANSFERASE ENZYMES GlaxoSmithKline Biologicals S.A. (BE) 2024-06-26 EP disclosed
EP-4010467-B1 MUTATED PGLB OLIGOSACCHARYLTRANSFERASE ENZYMES GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2024-04-24 EP disclosed
EP-4291673-A2 MUTATED PGLB OLIGOSACCHARYLTRANSFERASE ENZYMES GlaxoSmithKline Biologicals SA (BE) 2023-12-20 EP disclosed
US-20220403347-A1 MUTATED PGLB OLIGOSACCHARYLTRANSFERASE ENZYMES GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2022-12-22 US disclosed
WO-2022171679-A2 PROTEIN GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2022-08-18 WO disclosed
EP-4043561-A1 COMPOSITIONS AND METHODS FOR PROTEIN GLYCOSYLATION GlaxoSmithKline Biologicals SA (BE) 2022-08-17 EP disclosed
EP-4010467-A1 MUTATED PGLB OLIGOSACCHARYLTRANSFERASE ENZYMES GlaxoSmithKline Biologicals SA (BE) 2022-06-15 EP disclosed
EP-3240895-B1 COMPOSITIONS AND METHODS FOR PROTEIN GLYCOSYLATION GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2022-01-26 EP disclosed
US-11015177-B2 Compositions and methods for protein glycosylation GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2021-05-25 US disclosed
WO-2021028303-A1 MUTATED PGLB OLIGOSACCHARYLTRANSFERASE ENZYMES GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2021-02-18 WO disclosed
US-20200181586-A1 COMPOSITIONS AND METHODS FOR PROTEIN GLYCOSYLATION GLAXOSMITHKLINE BIOLOGICALS, SA (BE) 2020-06-11 US disclosed
US-10577592-B2 Compositions and methods for protein glycosylation GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2020-03-03 US disclosed
US-20190078064-A1 COMPOSITIONS AND METHODS FOR PROTEIN GLYCOSYLATION GLAXOSMITHKLINE BIOLOGICALS, S.A. (BE) 2019-03-14 US disclosed
US-10150952-B2 Compositions and methods for protein glycosylation GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) 2018-12-11 US disclosed
US-20180002679-A1 COMPOSITIONS AND METHODS FOR PROTEIN GLYCOSYLATION GLAXOSMITHKLINE BIOLOGICALS, SA (BE) 2018-01-04 US disclosed
EP-3240895-A1 COMPOSITIONS AND METHODS FOR PROTEIN GLYCOSYLATION GlaxoSmithKline Biologicals S.A. (BE) 2017-11-08 EP disclosed
WO-2016107818-A1 COMPOSITIONS AND METHODS FOR PROTEIN GLYCOSYLATION GLYCOVAXYN AG (CH) 2016-07-07 WO disclosed
WO-2016107819-A1 COMPOSITIONS AND METHODS FOR PROTEIN GLYCOSYLATION GLYCOVAXYN AG (CH) 2016-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12559731-B2 Mutated PglB oligosaccharyl transferase enzymes OSTC, PGLS, O60361 PAX8 3663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.